Drug major Lupin gets USFDA nod for generic pain relieving medicine

Drug major Lupin on Thursday said its US arm Gavis has received approval from the US health regulator to market hydrocodone bitartrate and acetaminophen tablets, a pain relieving drug, in the American market.

Gavis Pharmaceuticals, a subsidiary of the company, has has received final approval for its Hydrocodone Bitartrate and Acetaminophen tablets from the US Food and Drug Administration (USFDA), Lupin said in a statement.

The company's product, which is indicated for relief from moderate to moderately severe pain, is a generic equivalent of Mikart Inc's Hydrocodone Bitartrate and Acetaminophen tablets.

According to IMS MAT sales data, Hydrocodone Bitartrate and Acetaminophen tablets had sales of $89.6 million in the US market.

Currently, Lupin has the fifth largest pipeline of abbreviated new drug application (ANDA) filings pending approval with the USFDA.

Cumulative filings of the company with the USFDA now stand at 339, with the company having received approvals for 198 products.

Lupin's shares were trading at Rs 1,425 apiece on the BSE, up 1.24 per cent from their previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel